Binding of an octylglucoside detergent molecule in the second substrate (S2) site of LeuT establishes an inhibitor-bound conformation

The first crystal structure of the neurotransmitter/sodium symporter homolog LeuT revealed an occluded binding pocket containing leucine and 2 Na+; later structures showed tricyclic antidepressants (TCAs) in an extracellular vestibule ≈11 Å above the bound leucine and 2 Na+. We recently found this region to be a second binding (S2) site and that binding of substrate to this site triggers Na+-coupled substrate symport. Here, we show a profound inhibitory effect of n-octyl-β-d-glucopyranoside (OG), the detergent used for LeuT crystallization, on substrate binding to the S2 site. In parallel, we determined at 2.8 Å the structure of LeuT-E290S, a mutant that, like LeuT-WT, binds 2 substrate molecules. This structure was similar to that of WT and clearly revealed an OG molecule in the S2 site. We also observed electron density at the S2 site in LeuT-WT crystals, and this also was accounted for by an OG molecule in that site. Computational analyses, based on the available crystal structures of LeuT, indicated the nature of structural arrangements in the extracellular region of LeuT that differentiate the actions of substrates from inhibitors bound in the S2 site. We conclude that the current LeuT crystal structures, all of which have been solved in OG, represent functionally blocked forms of the transporter, whereas a substrate bound in the S2 site will promote a different state that is essential for Na+-coupled symport.

[1]  Eric Gouaux,et al.  Antidepressant binding site in a bacterial homologue of neurotransmitter transporters , 2007, Nature.

[2]  G. Rudnick Mechanisms of Biogenic Amine Neurotransmitter Transporters , 2002 .

[3]  Harel Weinstein,et al.  The mechanism of a neurotransmitter:sodium symporter--inward release of Na+ and substrate is triggered by substrate in a second binding site. , 2008, Molecular cell.

[4]  Randy J. Read,et al.  Phaser crystallographic software , 2007, Journal of applied crystallography.

[5]  R. Blakely,et al.  Monoamine transporter gene structure and polymorphisms in relation to psychiatric and other complex disorders , 2002, The Pharmacogenomics Journal.

[6]  Kevin Cowtan,et al.  research papers Acta Crystallographica Section D Biological , 2005 .

[7]  Da-Neng Wang,et al.  LeuT-Desipramine Structure Reveals How Antidepressants Block Neurotransmitter Reuptake , 2007, Science.

[8]  Eric Gouaux,et al.  A Competitive Inhibitor Traps LeuT in an Open-to-Out Conformation , 2008, Science.

[9]  J. Javitch,et al.  How did the neurotransmitter cross the bilayer? A closer view , 2005, Current Opinion in Neurobiology.

[10]  R. Gainetdinov,et al.  Plasma membrane monoamine transporters: structure, regulation and function , 2003, Nature Reviews Neuroscience.

[11]  Jonathan A. Javitch,et al.  Mechanism of chloride interaction with neurotransmitter:sodium symporters , 2007, Nature.

[12]  R. Rothman,et al.  Monoamine transporters and psychostimulant drugs. , 2003, European journal of pharmacology.

[13]  Alexander D. MacKerell,et al.  All-atom empirical potential for molecular modeling and dynamics studies of proteins. , 1998, The journal of physical chemistry. B.

[14]  B. Greenberg,et al.  Serotonin transporter missense mutation associated with a complex neuropsychiatric phenotype , 2003, Molecular Psychiatry.

[15]  R. Kinne,et al.  Interactions of alkylglucosides with the renal sodium/D-glucose cotransporter. , 1996, Biochimica et biophysica acta.

[16]  Eric Gouaux,et al.  Crystal structure of a bacterial homologue of Na+/Cl--dependent neurotransmitter transporters , 2005, Nature.

[17]  J. Sutcliffe,et al.  Allelic heterogeneity at the serotonin transporter locus (SLC6A4) confers susceptibility to autism and rigid-compulsive behaviors. , 2005, American journal of human genetics.

[18]  W. Schaffner,et al.  A rapid, sensitive, and specific method for the determination of protein in dilute solution. , 1973, Analytical biochemistry.

[19]  Kevin J. Naidoo,et al.  Carbohydrate solution simulations: Producing a force field with experimentally consistent primary alcohol rotational frequencies and populations , 2002, J. Comput. Chem..

[20]  A. Villringer,et al.  Increased serotonin transporter availability in the brainstem of migraineurs , 2007, Journal of Neurology.

[21]  Stephan O. Krause,et al.  Identification and Selective Inhibition of the Channel Mode of the Neuronal GABA Transporter 1 , 2005, Molecular Pharmacology.

[22]  W. Delano The PyMOL Molecular Graphics System , 2002 .

[23]  Randy J Read,et al.  Electronic Reprint Biological Crystallography Phenix: Building New Software for Automated Crystallographic Structure Determination Biological Crystallography Phenix: Building New Software for Automated Crystallographic Structure Determination , 2022 .

[24]  G. Rudnick,et al.  Stable expression of biogenic amine transporters reveals differences in inhibitor sensitivity, kinetics, and ion dependence. , 1994, The Journal of biological chemistry.

[25]  J. Mindell,et al.  The uncoupled chloride conductance of a bacterial glutamate transporter homolog , 2007, Nature Structural &Molecular Biology.

[26]  M. Meegan,et al.  Recent developments in the design of anti-depressive therapies: targeting the serotonin transporter. , 2008, Current medicinal chemistry.

[27]  G. Richerson,et al.  Role of the GABA transporter in epilepsy. , 2004, Advances in experimental medicine and biology.

[28]  J. Javitch,et al.  Monitoring the function of membrane transport proteins in detergent-solubilized form , 2007, Proceedings of the National Academy of Sciences.

[29]  Grégori Gerebtzoff,et al.  Enhancement of drug absorption by noncharged detergents through membrane and P-glycoprotein binding , 2006, Expert opinion on drug metabolism & toxicology.

[30]  Laxmikant V. Kalé,et al.  Scalable molecular dynamics with NAMD , 2005, J. Comput. Chem..

[31]  S. Amara,et al.  Neurotransmitter transporters as molecular targets for addictive drugs. , 1998, Drug and alcohol dependence.